Otonomy Announces FDA Acceptance of OTIPRIO® Supplemental New Drug Application Filing for Acute Otitis Externa
18 juil. 2017 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, July 18, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy to Host Key Opinion Leader Meeting for Investors on Ménière's Disease
20 juin 2017 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, June 20, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Announces OTIPRIO® Data Presentation and Symposium at the American Society of Pediatric Otolaryngology Annual Meeting
12 mai 2017 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 12, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy to Report First Quarter 2017 Financial Results and Provide Corporate Update
27 avr. 2017 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, April 27, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
02 mars 2017 16h18 HE
|
Otonomy, Inc.
Topline data for OTO-104 Phase 3 trials in Ménière’s disease expected in 2H2017 Implemented changes to commercial organization to improve OTIPRIO® sales performance Company to host conference call...
Otonomy to Present at Cowen and Company Health Care Conference
28 févr. 2017 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy to Report Fourth Quarter and Full Year 2016 Financial Results and Provide Corporate Update
24 févr. 2017 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Feb. 24, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Initiates Patient Enrollment in Phase 2 Clinical Trial of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss
19 janv. 2017 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Jan. 19, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Provides Corporate and Product Pipeline Update
09 janv. 2017 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Announces Positive Top-Line Results from Phase 3 Clinical Trial of OTIPRIO® in Patients with Acute Otitis Externa
05 janv. 2017 07h00 HE
|
Otonomy, Inc.
SAN DIEGO, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...